Comparative Tolerability,Safety and Efficacy of Tablet Formulations of Twice-Daily Clarithromycin 250 mg versus Once-Daily Extended-Release Clarithromycin 500 mg in Pediatric and Adolescent Patients
Restricted accessResearch articleFirst published online September, 2006
Comparative Tolerability,Safety and Efficacy of Tablet Formulations of Twice-Daily Clarithromycin 250 mg versus Once-Daily Extended-Release Clarithromycin 500 mg in Pediatric and Adolescent Patients
Clarithromycin is widely used to treat respiratory tract and superficial skin infections in pediatric and adult populations. Using clinical endpoints and 7-day therapy, we compared the efficacy of clarithromycin 250 mg tablets given twice daily versus clarithromycin 500 mg extendedrelease tablets given once daily in ambulatory children and adolescents 6 to 16 years old. Of the 199 evaluable patients, 124 were infected with group A streptococcal pharyngitis, 39 with sinusitis, 21 with ambulatory pneumonia, and 15 with superficial skin infections. The overall cure rate exceeded 90% for each treatment group. Discontinuation rates and adverse events were 4.5% and 24.6%, respectively.
Get full access to this article
View all access options for this article.
References
1.
Arguedas A, Loaiza C, Rodriguez F, et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. J Chemother. 1997;9:44-50.
2.
Gooch WM, Adelglass J, Kelsey DK, et al. Loracarbef versus clarithromycin in children with acute otitis media with effusion. Clin Ther. 1999;21:711-722.
3.
Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995;14:471-477.
4.
McCarty J, Hedrick JA, Gooch WM. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther. 2000;17:14-26.
5.
Syrogiannopoulos GA, Bozdogan B, Grivea IN, et al.Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 2004;23:857-865.
6.
Takker U, Dzyublyk O, Busman T, et al. Comparison of 5 days of extendedrelease clarithromycin versus 10 days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: results of a multicenter, double-blind, randomized study in adolescent and adult patients. Curr Med Res Opin. 2003;19:421-429.
7.
Guay DR, Gustavson LE, Devcich KJ, et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther. 2001;23:566-577.
8.
Green M, Martin JM, Barbadora KA, et al. Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother. 2004;48:473-476.
9.
Linder JA, Stafford RS. Erythromycin-resistant group A streptococci. N Engl J Med. 2002;347:614-615; author reply 614-615.
10.
Shulman ST, Tanz R, Kabat W.Erythromycin-resistant group A streptococci.N Engl J Med. 2002;347:614-615.
11.
Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40:1785-1791.
12.
Dietrich DW, Auld DB, Mermel LA. Community-acquired methicillin-resistant Staphylococcus aureus in southern New England children. Pediatrics. 2004;113:347-352.
13.
Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000–2002). Diagn Microbiol Infect Dis. 2003;47:515-525.
14.
Block SL. Short-course antimicrobial therapy of streptococcal pharyngitis. Clin Pediatr. 2003;42:663-671.
15.
Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics. 2004;113:866-882.
16.
Kaplan EL, Gooch III WM, Notario GF, et al. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). Clin Infect Dis. 2001;32:1798-1802.
17.
Quinn J, Ruoff GE, Ziter PS. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2003;25:422-443.
18.
McCarty J, Hedrick JA, Gooch WM. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther. 2000;17:14-26.
19.
Cohen R, Reinert P, De La Rocque F, et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 2002;21:297-303.
20.
Portier H, Filipecki J, Weber P, et al. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, open-label, randomized study. J Antimicrob Chemother. 2002; 49:337-344.
21.
Bassetti M, Manno G, Collida A, et al. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis. 2000;6:80-83.
22.
Tzelepi E, Kouppari G, Mavroidi A, et al. Erythromycin resistance amongst group A beta-haemolytic streptococci isolated in a paediatric hospital in Athens, Greece. J Antimicrob Chemother. 1999;43:745-746.
23.
Bisno AL, Gerber MA, Gwaltney JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis. 2002;35:113-125.
24.
Riffer E, Spiller J, Palmer R, et al. Once daily clarithromycin extendedrelease vs twice-daily amoxicillin/ clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Curr Med Res Opin. 2005;21:61-70.
25.
American Academy of Pediatrics Sub-committee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451-1465.
26.
American Academy of Pediatrics Sub-committee on Management of Sinusitis and Committee on Quality Improvement Clinical Practice Guideline: Management of Sinusitis. Pediatrics. 2001;108:798-808.
27.
Gotfried MH. Clarithromycin extended-release tablet: a therapeutic review. Expert Rev Anti Infect Ther. 2003;1:9-20.
28.
Block SL, Hedrick J, Harrison CJ, et al. Pneumococcal serotypes from acute otitis media in rural Kentucky. Pediatr Infect Dis J. 2002;21:859-865.
29.
Whitney CG, Farley MM, Hadler J, et al, for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
30.
Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: populationbased assessment. Lancet. 2005;365: 855-863.
31.
Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of communityacquired pneumonia in children. Pediatr Infect Dis J. 1998;17:865-871.
32.
Tack KJ, Keyserling CH, McCarty J, et al. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob Agents Chemother. 1997;41:739-742.
33.
Hebert AA, Still JG, Reuman PD. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children. Pediatr Infect Dis J. 1993;12:S112-S117.
34.
Parish LC. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Clarithromycin Study Group. Int J Dermatol. 1993;32:528-532.
